WO2021249012A9 - Coronavirus vaccine compositions, methods, and uses thereof - Google Patents

Coronavirus vaccine compositions, methods, and uses thereof Download PDF

Info

Publication number
WO2021249012A9
WO2021249012A9 PCT/CN2021/087066 CN2021087066W WO2021249012A9 WO 2021249012 A9 WO2021249012 A9 WO 2021249012A9 CN 2021087066 W CN2021087066 W CN 2021087066W WO 2021249012 A9 WO2021249012 A9 WO 2021249012A9
Authority
WO
WIPO (PCT)
Prior art keywords
methods
vaccine compositions
coronavirus vaccine
coronavirus
collagen
Prior art date
Application number
PCT/CN2021/087066
Other languages
French (fr)
Other versions
WO2021249012A1 (en
Inventor
Peng Liang
Joshua Liang
Original Assignee
Sichuan Clover Biopharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Clover Biopharmaceuticals, Inc. filed Critical Sichuan Clover Biopharmaceuticals, Inc.
Priority to PCT/CN2021/093895 priority Critical patent/WO2021249116A1/en
Priority to JP2022576439A priority patent/JP2023530434A/en
Priority to PCT/CN2021/099285 priority patent/WO2021249451A1/en
Priority to CN202180002838.2A priority patent/CN114206946B/en
Priority to CN202311163567.6A priority patent/CN117180416A/en
Priority to EP21777614.5A priority patent/EP3947475A4/en
Priority to CN202311163597.7A priority patent/CN117180417A/en
Priority to US17/489,572 priority patent/US11389528B2/en
Publication of WO2021249012A1 publication Critical patent/WO2021249012A1/en
Publication of WO2021249012A9 publication Critical patent/WO2021249012A9/en
Priority to US17/832,664 priority patent/US20230096093A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides a complex of coronavirus antigens joined by in-frame fusion to a C-terminal portion of a collagen to form a disulfide bond-linked trimeric fusion protein. Also provided herein are methods for preventing the infection or producing the recombinant peptides and diagnostic methods.
PCT/CN2021/087066 2020-06-10 2021-04-13 Coronavirus vaccine compositions, methods, and uses thereof WO2021249012A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PCT/CN2021/093895 WO2021249116A1 (en) 2020-06-10 2021-05-14 Coronavirus vaccine compositions, methods, and uses thereof
JP2022576439A JP2023530434A (en) 2020-06-10 2021-06-10 Coronavirus vaccine compositions, methods and uses thereof
PCT/CN2021/099285 WO2021249451A1 (en) 2020-06-10 2021-06-10 Coronavirus vaccine compositions, methods, and uses thereof
CN202180002838.2A CN114206946B (en) 2020-06-10 2021-06-10 Coronavirus vaccine compositions, methods and uses thereof
CN202311163567.6A CN117180416A (en) 2020-06-10 2021-06-10 Coronavirus vaccine compositions, methods and uses thereof
EP21777614.5A EP3947475A4 (en) 2020-06-10 2021-06-10 Coronavirus vaccine compositions, methods, and uses thereof
CN202311163597.7A CN117180417A (en) 2020-06-10 2021-06-10 Coronavirus vaccine compositions, methods and uses thereof
US17/489,572 US11389528B2 (en) 2020-06-10 2021-09-29 Coronavirus vaccine compositions, methods, and uses thereof
US17/832,664 US20230096093A1 (en) 2020-06-10 2022-06-05 Coronavirus vaccine compositions, methods, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020095269 2020-06-10
CNPCT/CN2020/095269 2020-06-10

Publications (2)

Publication Number Publication Date
WO2021249012A1 WO2021249012A1 (en) 2021-12-16
WO2021249012A9 true WO2021249012A9 (en) 2022-03-17

Family

ID=78845177

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/087066 WO2021249012A1 (en) 2020-06-10 2021-04-13 Coronavirus vaccine compositions, methods, and uses thereof

Country Status (1)

Country Link
WO (1) WO2021249012A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
US11931410B1 (en) 2022-01-27 2024-03-19 Shenzhen Rhegen Biotechnology Co., Ltd. SARS-CoV-2 mRNA vaccine and preparation method and use thereof
CN116549625A (en) * 2022-01-27 2023-08-08 四川三叶草生物制药有限公司 Coronavirus vaccine compositions, methods and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7268116B2 (en) * 2003-10-02 2007-09-11 Genhunter Corp. Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins

Also Published As

Publication number Publication date
WO2021249012A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
WO2021249012A9 (en) Coronavirus vaccine compositions, methods, and uses thereof
WO2021249116A9 (en) Coronavirus vaccine compositions, methods, and uses thereof
PE20040554A1 (en) VACCINES INVOLVING FUSION PROTEINS
PT2360176E (en) Hybrid and tandem expression of neisserial derived proteins
HRP20200503T1 (en) Fusion proteins
RU2021132097A (en) RSV F PROTEINS IN PRE-FUSION CONFORMATION AND THEIR APPLICATIONS
PL366826A1 (en) Reducing the immunogenicity of fusion proteins
IL152507A0 (en) Methods and compositions for impairing multiplication of hiv-1
WO2007115837B1 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
EP4223773A3 (en) Methods
GB2598494A (en) A subunit vaccine for treatment or prevention of a respiratory tract infection
RU2017132689A (en) Fc α-chain fused high affinity IgE receptor
WO2021249013A9 (en) Vaccine compositions, methods, and uses thereof
DE60324406D1 (en) MODIFIED FACTOR VIII
PE20220500A1 (en) FUSION POLYPEPTIDE COMPRISING THE Fc REGION OF IMMUNOGLOBULIN AND GDF15
BR0309491A (en) Vaccine composition, immunogenic composition, use of an e7 protein and neutralizing antibodies
ATE177843T1 (en) PEPTOMERS WITH INCREASED IMMUNOGENICITY
MX2020012103A (en) Improved fviii fusion protein and use thereof.
WO2023046085A8 (en) Tpo mimetic fusion proteins and methods of use
WO2020026045A3 (en) Leader sequence for higher expression of recombinant proteins
WO2004018511A3 (en) Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins
WO2021249011A9 (en) Hiv vaccine compositions, methods, and uses thereof
WO2021252974A3 (en) Collagen-targeted fusion proteins and antibodies
MX2022011642A (en) Ngr conjugates and uses thereof.
DE60139952D1 (en) IMMUNOGENIC GLYCOPEPTIDE. SCREENING AND MANUFACTURING METHOD AND USES

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21821644

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21821644

Country of ref document: EP

Kind code of ref document: A1